Five-Plus-Five Equals A Focus On Execution At Lilly In 2023
Approvals Near For Four New Drugs, One New Indication
Executives told Scrip the company is ready to move five programs into Phase III and launch five products this year, including an obesity indication for Mounjaro, but one drug has since received a CRL.
You may also be interested in...
Mounjaro’s fourth quarter sales disappointed some analysts, but the launch remains off to a strong start. Donanemab now on track for full approval in Alzheimer’s, CEO Ricks pledges.
Lilly plans to seek traditional approval for its amyloid-clearing antibody after the Phase III TRAILBLAZER-ALZ 2 trial reads out in Q2, but it loses important ground in reimbursement negotiations.
Daily notebook from the J.P. Morgan Healthcare Conference: Big pharma execs weigh in on business development strategy, Sage CEO Barry Green discusses how the Inflation Reduction Act should spur deal-making and bluebird talks about gene therapy commercialization plans.